Patents by Inventor Long Mao

Long Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230026438
    Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 26, 2023
    Inventors: Long Mao, Xiao Xu, Namir Shaabani, Can Jin
  • Patent number: 11548897
    Abstract: Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: January 10, 2023
    Assignee: Novartis AG
    Inventors: Ying Huang, Bo Liu, Liang Mao, Long Wang, Liladhar Murlidhar Waykole, Lijun Zhang
  • Patent number: 11517512
    Abstract: Disclosed herein are personal care compositions comprising Zn:usnate complexes having a 1:2 zinc to usnate molar ratio. Methods of making and using the compositions are also provided. The personal care compositions may include a cleansing component and an antibacterial component, wherein the antibacterial component comprises Zn:usnate complexes having a 1:2 zinc to usnate molar ratio.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: December 6, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Stanislav Jaracz, Long Pan, Karthik Sambanthamoorthy, Junhong Mao, Aixing Fan
  • Patent number: 11498922
    Abstract: The present invention relates to methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 15, 2022
    Assignees: ACEA Therapeutics, Inc., Hangzhou ACEA Pharmaceutical Research Co., Ltd., Zhejiang ACEA Pharmaceuticals Co., Ltd.
    Inventors: Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xi-aopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
  • Publication number: 20210309642
    Abstract: The invention relates to solid forms of certain N-(pyrimidinyloxy)acrylamide derivatives that are useful in the treatment of proliferation and immunological disorders and other diseases related to the dysregulation of kinases including EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK. The invention provides methods of making these materials and their salts and polymorphs, and intermediates for preparing these materials, as well as pharmaceutical compositions comprising these materials. The solid forms and pharmaceutical compositions comprising them are useful to treat conditions including a proliferation disorder, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye, rheumatoid arthritis, or lupus.
    Type: Application
    Filed: August 9, 2018
    Publication date: October 7, 2021
    Applicants: ACEA Therapeutics, Inc., HANGZHOU ACEA PHARMACEUTICAL RESEARCH CO., LTD., ZHEJIANG ACEA PHARMACEUTICALS CO., LTD.
    Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kunhua DONG, Liang CHEN, Bojie WENG, Xiaopeng MO, Kongen DAI, Yimei BAO, Jian WU, Bin LIANG, Guanglin ZHOU, Zhen WANG
  • Publication number: 20210300931
    Abstract: Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC AND TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Application
    Filed: April 7, 2017
    Publication date: September 30, 2021
    Applicants: ACEA Therapeutics, Inc., Hangzhou ACEA Pharmaceutical Research Co., Ltd., Zhejiang ACEA Pharmaceuticals Co., Ltd.
    Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xi-aopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG
  • Patent number: 11007197
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 18, 2021
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Publication number: 20210100802
    Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 8, 2021
    Applicant: ACEA Therapeutics, Inc.
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
  • Patent number: 10799504
    Abstract: The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Grant
    Filed: January 12, 2013
    Date of Patent: October 13, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Publication number: 20200129516
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 30, 2020
    Applicant: ACEA Therapeutics, Inc.
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
  • Patent number: 10596174
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 24, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Patent number: 10562918
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: February 18, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Patent number: 10533011
    Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 14, 2020
    Assignee: ACEA THERAPEUTICS, INC.
    Inventors: Long Mao, Jia Liu, Yile Chen, Yuning Hua, Kongen Dai, Yimei Bao, Bojie Weng, Xiaopeng Mo, Jian Wu, Xiao Xu, Wanhong Xu, Xiaobo Wang
  • Patent number: 10449196
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 22, 2019
    Assignee: ACEA Therapeutics, Inc.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Publication number: 20180312510
    Abstract: Provided are methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3 (D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 1, 2018
    Applicant: ACEA THERAPEUTICS, INC.
    Inventors: Long MAO, Jia LIU, Yile CHEN, Yuning HUA, Kongen DAI, Yimei BAO, Bojie WENG, Xiaopeng MO, Jian WU, Xiao XU, Wanhong XU, Xiaobo WANG
  • Publication number: 20180251475
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
    Type: Application
    Filed: January 29, 2018
    Publication date: September 6, 2018
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
  • Patent number: 9920074
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 20, 2018
    Assignee: ACEA BIOSCIENCES INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Publication number: 20180008607
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 11, 2018
    Applicant: Acea Biosciences Inc.
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI
  • Patent number: 9763949
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: September 19, 2017
    Assignee: ACEA BIOSCIENCES INC.
    Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
  • Publication number: 20170224689
    Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.
    Type: Application
    Filed: February 17, 2017
    Publication date: August 10, 2017
    Applicant: ACEA BIOSCIENCES INC.
    Inventors: Xiao XU, Xiaobo WANG, Long MAO, Li ZHAO, Biao XI